MENU
Agenda
Opens September 29th at 8:00AM PDT, 11:00AM EDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

2nd Annual PAWS FOR A CURE Research Symposium

Translational Potential Of Comparative Approaches To Accelerate Drug
Development In Shared Childhood & Canine Cancers  
 
Join the world’s leaders
in pediatric and veterinary cancer research, pharma and biotech, human cancer and animal health foundations, and childhood and canine cancer patients as we explore the state-of-the-art in science in comparative cancer research. Our goal is to forge new collaborations and accelerate progress in cancers shared by children and man’s best friend. We welcome you to Paws for a Cure 2020!
 
Co-Presented by: 
In Partnership with:
 
This year's symposium experience will feature:
a virtual auditorium with interactive,
multi-disciplinary seminars and discussions of cutting edge scientific content,
break-out sessions, a virtual lounge for networking with speakers and presenters, and more. 

Speakers
  • Global Head, Oncology Development and Global Head, Pediatric Innovation, Sanofi Inc. Former Chair, Children's Oncology Group
  • Vice-President and co-founder of Progressive O&P, Inc.
  • Team Leader for the Cell and Tissue Products Team in the Division of Animal Bioengineering and Cellular Therapies
  • Director of PET Imaging Center of the University of Missouri, Director of the Tom and Betty Scott Endowed Program in Veterinary Oncology
  • President & Chief Executive Officer for TVAX Biomedical
  • Professor in the Department of Neurosurgery, University of Alabama, Birmingham
  • Professor of Immunology in the DCS and Director of the Center for Immune and Regenerative Medicine, Colorado State University
  • Associate Professor of Orthopaedic Surgery, Duke University
  • Assistant Research Professor,Cummings School of Veterinary Medicine, Tufts University
  • Assistant Professor, Integrated Cancer Genomics Division, TGen
  • Dean of the University of Missouri College of Veterinary Medicine (CVM)
  • Professor of Pediatrics, Pathology, Biomedical Engineering and General Medical Sciences at Case Western Reserve University School of Medicine
  • Director, Parker Institute for Cancer Immunotherapy University of Pennsylvania Perelman School of Medicine
  • Expert Veterinary and Biomedical Scientist, Morris Animal Foundation
  • Vice Chair and Professor of Biostatistics and Bioinformatics at Duke University
  • Senior Director of Pediatric Oncology, Bristol-Myers Squibb
  • Director, Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
  • Professor of Pediatrics and DiMarco Family Endowed Chair in Cell Based Therapy at Nationwide Children's Hospital
  • Research Professor at Cummings School of Veterinary Medicine, Tufts University & Molecular Oncology Research Institute at Tufts Medical Center
  • Professor of Medicine & Pathobiology, University of Pennsylvania School of Veterinary Medicine
  • Director of Program Management for the Center for Technical and Operations Support
  • Professor and Director of the Flint Animal Cancer Center Stephen Withrow Presidential Chair in Oncology
  • Associate Director for Pediatric Oncology in the FDA's Oncology Center of Excellence, Office of the Commissioner
  • Director of Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
  • Assistant Prof, Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital Principal Investigator, Center for Childhood Cancer, Nationwide Children's Hospital The Ohio State University
  • Assistant Professor of Neurosurgery, Pediatrics & Principal Investigator, RNA Engineering Laboratory in the Preston A. Wells, Jr. Center for Brain Tumor Therapy & UF Brain Tumor Immunotherapy
  • CEO & Co-Founder, PEEL Therapeutics / Pediatric Hematologist-Oncologist
  • Director, Translational Brain Tumor Laboratory, Children's Hospital of Philadelphia
  • Program Director at the ImmunoOncology Branch in the Developmental Therapeutics Program in the Division of Cancer Treatment & Diagnosis, National Cancer Institute
  • President and Research Director of the Translational Genomics Research Institute (TGen)
  • Professor and Associate Director of Computational Biology, JAX Laboratory
  • Assistant Head, Clinical Biomarkers Translational Oncology, Merck

Show Resources
You May Also Like
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
SEP 29, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 29, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Due to the fact that many large events and scientific conferences have been cancelled, we want to provide you with an outlet to present your research and learn from others in our community....
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 7 th Ann...
OCT 28, 2020 7:00 AM GMT, 12:30PM IST, 3:00PM SGT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
OCT 28, 2020 7:00 AM GMT, 12:30PM IST, 3:00PM SGT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Each step in a diagnostic test's journey-from raw material extraction to patient administration-can influence outcomes....
FEB 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
FEB 10, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is pleased to announce the 10th annual Laboratory Animal Science (LAS) Virtual Conference which will take place on February 10th 2021. This is the premier on...
OCT 13, 2020 12:00 PM BST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
OCT 13, 2020 12:00 PM BST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
abstract...
Speakers

More great speakers added daily!


  • Peter C. Adamson, MD
    Global Head, Oncology Development and Global Head, Pediatric Innovation, Sanofi Inc. Former Chair, Children's Oncology Group
    Biography

      For nearly a decade, Peter C. Adamson, MD served as Chair of the Children's Oncology Group (COG), a National Cancer Institute (NCI) supported international consortium of more than 220 childhood centers that conducts clinical-translational research, including large-scale clinical trials, in children with cancer. After a long and distinguished career in academia, Dr. Adamson recently joined Sanofi, Inc. as Global Head, Oncology Development and Global Head, Pediatric Innovation. Dr. Adamson is Professor Emeritus at the Perelman School of Medicine of the University of Pennsylvania. He is Board Certified in Pediatric Hematology/Oncology and Clinical Pharmacology. Dr. Adamson was appointed by President Obama and serves on the National Cancer Advisory Board (NCAB) and has served as a member of the Blue Ribbon Panel for Vice President Biden's National Cancer Moonshot Initiative. Prior to becoming Chair of the COG in 2011, Dr. Adamson was Director for Clinical and Translational Research at The Children's Hospital of Philadelphia, as well as Chief of the Division of Clinical Pharmacology and Therapeutics. Other past roles include being co-Director of the University of Pennsylvania's - CHOP Clinical Translational Science Award (CTSA), Program Director of the General Clinical Research Center (GCRC) and Principal Investigator of CHOP's Pediatric Pharmacology Research Unit (PPRU).

    • Dan Bastian (Survivor)
      Vice-President and co-founder of Progressive O&P, Inc.
      Biography

        Dan Bastian is Vice-President and co-founder of Progressive O&P, Inc., since its incorporation in 1999. Dan has been an American Board Certified Prosthetist since 1996; he earned his Bachelor of Science degree in Computer Science from Marist College in 1987.

        In 1980, at the age of 15, he was diagnosed with osteogenic sarcoma in his right leg. After countless unsuccessful surgeries to repair the damaged bone and musculature, in 1990 Dan made the decision to have his right leg amputated six inches below his hip. He has walked with a prosthesis ever since. While working as a System Programmer for IBM, Dan volunteered at Memorial Sloane Kettering, spending time with pediatric patients about to undergo amputation and sharing pictures of himself skiing and other activities to reassure them that an active life wasn’t over after limb loss.

        This experience motivated him to return to school and earn a degree in Prosthetics. Over twenty years ago Dan, along with his business partner, Sal Martella, opened Progressive O&P, a successful clinical practice providing compassionate care for adults, children, and veterans needing prosthetic and orthotic solutions.

        As a Certified Prosthetist (CP), Dan has dedicated his career to helping patients living with limb loss. He is a member of the Amputee Coalition of America, the American Academy of Orthotists and Prosthetists, the National Amputee Golf Association (life member), and the Disabled Sports Association and former Board member of the National Association for the Advancement of Orthotics and Prosthetics (NAAOP). Dan lives with his family Massapequa.

      • Lynne Boxer, DVM
        Team Leader for the Cell and Tissue Products Team in the Division of Animal Bioengineering and Cellular Therapies
        Biography

          Dr. Boxer obtained her veterinary degree from the Virginia-Maryland Regional College of Veterinary Medicine. After graduation, Dr. Boxer practiced equine medicine in an ambulatory practice in California before joining FDA’s Center for Veterinary Medicine. Dr. Boxer has been with CVM for 14 years as a Veterinary Medical Officer in the Office of New Animal Drug Evaluation. Dr. Boxer leads the Center in developing regulatory and review policy for animal cells, tissues, and cell- or tissue-based products, as well as conducting educational outreach. In her current role, she is the Team Leader for the Cell and Tissue Products Team in the Division of Animal Bioengineering and Cellular Therapies.

        • Jeffrey Bryan, DVM, MS, PhD, DACVIM-Oncology
          Director of PET Imaging Center of the University of Missouri, Director of the Tom and Betty Scott Endowed Program in Veterinary Oncology
          Biography

            Dr. Jeffrey Bryan earned a Bachelor of Science degree in veterinary science from the University of California - Davis in 1991. He received his D.V.M. from the University of California - Davis in 1993. He worked as an Associate Veterinarian from 1993-1995 and served as Medical Director from 1995-2002 of the Irving Street Veterinary Hospital in San Francisco, CA. Bryan then completed a medical oncology residency, a Masters of Biomedical Sciences, and a PhD in Pathobiology at the University of Missouri. He received certification by the American College of Veterinary Internal Medicine in Oncology 2005. He is the Director of the Tom and Betty Scott Endowed Program in Veterinary Oncology, the Director of PET Imaging Center of the University of Missouri, NextGen Precision Health Faculty Research Lead for Cancer Research, and the Associate Director of Comparative Oncology for Ellis Fischel Cancer Center. Dr. Bryan’s research focuses on comparative examination of cancers in companion animals to better understand cancers in all species. His particular areas of interest are targeted imaging and therapy, epigenetics, and immunotherapy of cancers. He directs the PET Imaging Center, which seeks to develop novel PET imaging agents for cancer diagnosis, localization, and prognostication. He studies DNA methylation of canine non-Hodgkin lymphoma. He studies immunotherapy in companion dogs including investigating fetal microchimerism.

          • Wayne Carter, DVM, PhD, Diplomate ACVIM
            President & Chief Executive Officer for TVAX Biomedical
            Biography

              Dr. Carter serves as the president and chief executive officer for TVAX Biomedical, a novel cancer immunotherapy company focused on brain cancer and several difficult to treat cancers. He joined TVAX in 2019 and also serves as a member of the Board of Directors. Prior to that, he served as the president and CEO of BioNexus KC leading the transformation of the Kansas City region into a nationally recognized center of excellence in human and animal health research, development and commercialization. Dr. Carter has more than 18 years of Fortune 500 experience in pharmaceutical and nutrition R&D. In his role at Pfizer as executive director of Global Clinical Technologies, he accelerated the development of many drugs using novel clinical technologies. His board appointments include Acenxion, MRI Global, University of Kansas Center for Research, and the One Health Commission. Dr. Carter received his BS, DVM, and PhD in Immunology from Purdue University.

            • Melissa Renee Chambers, DVM, MD
              Professor in the Department of Neurosurgery, University of Alabama, Birmingham
              Biography

                As a veterinarian and neurosurgeon, Dr. Chambers is a strong proponent of the One Health Initiative, an effort to improve animal and public health worldwide and strengthen medicine by working together. She is the founder of the Alabama Comparative Oncology Network, principal investigator of the Southeastern Comparative Oncology Network, and founding member of the Comparative Brain Tumor Consortium at the Center for Cancer Research, NIH National Cancer Institute - each a collaboration of veterinary and medical scientists and clinicians working together to identify genetic targets for treatment of disease through comparative genomics. Dr. Chambers is the principal investigator of the "CANINE" immunotherapy trial, a collaboration between neuroscientists and clinicians at UAB and regional colleges of veterinary medicine funded by the NIH as part of the Cancer Moonshot Initiative to support cancer research. The research is aimed at identifying histopathologic and genetic similarities and evaluating novel therapies of brain tumors in both people and pets.

              • Steven Dow, PhD
                Professor of Immunology in the DCS and Director of the Center for Immune and Regenerative Medicine, Colorado State University
                Biography
                  Dr. Dow received his DVM degree from the University of Georgia and completed a residency in small animal internal medicine at Colorado State University. He then completed a PhD program in Comparative Pathology in the laboratory of Ed Hoover at Colorado State University. After that, Dr. Dow completed a post-doctoral fellowship at the National Jewish Center in the laboratory of Dr. Terry Potter, before joining the faculty of the Department of Clinical Sciences at CSU in 2002. He is currently a professor of immunology in the DCS and the director of the Center for Immune and Regenerative Medicine at CSU.
                • William Eward, DVM, PhD, MD
                  Associate Professor of Orthopaedic Surgery, Duke University
                  Biography

                    Having spent his childhood in the company of a wide variety of animals, Dr. Eward fulfilled a lifelong dream of becoming a small animal veterinarian in 2000 when he graduated from Auburn University's College of Veterinary Medicine. He was particularly captivated by his patients with cancer and decided to pursue this interest further. In 2002, he returned to school, receiving an MD degree from the University of Vermont. He currently is on faculty at Duke University with an adjunct appointment at the North Carolina State College of Veterinary Medicine. He spends the first part of the week taking care of humans with cancer and the latter part of the week taking care of animals with cancer. As an Orthopaedic Oncologist, he specializes in preserving and reconstructing limbs that have been jeopardized by a type of cancer called Sarcoma. Given his dual roles in human and animal health, Dr. Eward is committed to using a One Medicine approach to solving the terrible problem that cancer presents to all of us, whether we walk on two legs or four. He runs a lab at Duke that attempts to identify common elements between types of cancer across different species.

                  • Heather Gardner, DVM, PhD, DACVIM
                    Assistant Research Professor,Cummings School of Veterinary Medicine, Tufts University
                    Biography
                      Heather Gardner, DVM, DACVIM (Oncology) is an assistant research professor at the Cummings School of Veterinary Medicine at Tufts University. Her laboratory efforts center on comparative and translational oncology, using the tumor genome to inform novel therapeutic approaches. Dr. Gardner earned her DVM at Washington State University and completed her Residency in Medical Oncology at the Ohio State University before completing her PhD in Genetics at Tufts University.
                    • Will Hendricks, PhD
                      Assistant Professor, Integrated Cancer Genomics Division, TGen
                      Biography
                        Despite decades of progress in the clinical management of cancer and amidst recent innovations in genomics-guided medicine, we are still incapable of curing most patients who are diagnosed with advanced cancers. Our laboratory focuses on shifting paradigms in cancer treatment to enable cures through programs at the intersection of personalized medicine and comparative genomics. Dissecting biological determinants of therapeutic vulnerability in human melanoma through integrated analysis of genomic data. As part of the Stand Up to Cancer and Melanoma Research Alliance Dream Team, we are directing a clinical trial evaluating the hypothesis that genomics-guided drug selection can outperform physician-guided treatment in melanoma patients. Our laboratory is also working to characterize the biology of therapeutic sensitivity in melanoma cell lines through integrated analysis of comprehensive genomic, proteomic, and therapeutic data (including exome sequencing, array CGH, gene expression profiling, proteomic profiling, and high-throughput RNAi and drug screens). Hypotheses tested in vitro are contextualized through ongoing genomic analysis conducted in patient samples collected during the course of the genomics-guided clinical trial and alongside data available through public portals such as the TCGA. Mapping canine cancer landscapes for identification of actionable targets to guide comparative clinical trials. The work described above will support development of targeted inhibitors and combinations to spur further survival gains in human melanoma. Yet, testing novel agents, combinations, and dosing schedules can be challenging in human clinical trials due to their restrictive nature. Thus, we have turned to comparative oncology where it has long been recognized that extraordinary potential lies in aligning studies of sporadic cancers in pet dogs with drug development in human cancers. To this end, we have mapped the genomic landscape of canine mucosal melanoma, a common and lethal cancer in dogs that is equally deadly, but far less common, in humans. Integrated analysis has revealed genomic landscapes that resemble the human disease while also identifying novel therapeutically-relevant mutations that are reshaping our understanding of the human disease. We are now pursuing integrated comparative analysis of additional tumor types while these data are informing the development of comparative veterinary trials. Integrating genomic and therapeutic analyses of pediatric cancers. We have recently discovered frequent inactivating mutations and concomitant loss of the tumor suppressor SMARCA4 in the majority of cases of a rare cancer that afflicts girls and young women - small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). This mutation occurs amidst an otherwise stable cancer genome and thus provides a unique opportunity to study an isolated driver mutation of relevance to more genomically complex cancers with higher mutation rates (such as melanoma). More importantly, it provides a clear target in an extremely rare cancer for our ongoing pursuit of an empirically-derived therapeutic option for these underserved patients.
                      • Carolyn Henry, DVM, MS, DACVIM-Oncology
                        Dean of the University of Missouri College of Veterinary Medicine (CVM)
                        Biography

                          Dr. Henry was named Dean of the University of Missouri (MU) College of Veterinary Medicine (CVM) in February 2018 after serving as Interim Dean for six months. She is a tenured Full Professor with dual appointments at the CVM and the School of Medicine. She earned her DVM at Auburn University (1990) and practiced small animal and emergency medicine before completing an oncology residency/MS (DACVIM ’94). Henry served on the faculty at Washington State University from 1993 to 1997 before accepting a position at MU in 1997 to develop the oncology service. She is past president of both the Veterinary Cancer Society and the ACVIM Specialty of Oncology. Henry has served as the Mizzou Advantage One Health Facilitator (2010), Associate Director of Research for Ellis Fischel Cancer Center (2011) and Associate Dean for Research and Graduate Studies at the CVM (2013). Her research interests include canine bladder, bone, and mammary cancer and comparative oncology/cancer epidemiology.

                        • Alex Huang, MD, PhD
                          Professor of Pediatrics, Pathology, Biomedical Engineering and General Medical Sciences at Case Western Reserve University School of Medicine
                          Biography

                            Alex Y. Huang, MD, PhD is a tenured Professor of Pediatrics, Pathology, Biomedical Engineering and General Medical Sciences at Case Western Reserve University School of Medicine. He holds the Theresia G. & Stuart F. Kline Family Foundation Chair in Pediatric Oncology and serves as Director of the Pediatric Hematology-Oncology Fellowship Program at UH Rainbow Babies & Children’s Hospital and the Angie Fowler Adolescent & Young Adult Cancer Institute. Prior to his faculty appointment, Dr. Huang received combined B.S. & M.S. from University of Chicago, Medical Scientist Training Program (M.D./Ph.D.) from Johns Hopkins University, pediatric residency training at Johns Hopkins, Pediatric Hematology/Oncology fellowship at Johns Hopkins / NCI, and a postdoctoral fellowship at NIAID. Dr. Huang oversees immune cell-based and molecular-based therapeutic development as leader of Cancer Immunology Initiative and co-leader of the Hematopoiesis & Immune Cancer Biology Scientific Program at the Case Comprehensive Cancer Center. Dr. Huang serves on several scientific advisory committees including St. Baldrick’s Foundation, and as a member of the Cancer Immunotherapy & Preventing Working Group of the Cancer Moonshot Initiative Blue Ribbon Panel. Dr. Huang is an elected steering committee member of the Coalition for Pediatric Medical Research, and a member of the Children’s Oncology Group’s Bone Tumor Committee as well as the Osteosarcoma New Agent Task Force. Dr. Huang’s research focuses on fundamental cellular and molecular immunology, and in vivo onco-immunology, in areas such as tumor-associated macrophages, tumor-intrinsic immune checkpoint regulation, APC-T cell interaction and immune cellular trafficking using intravital two-photon microscopy.

                          • Carl June, MD
                            Director, Parker Institute for Cancer Immunotherapy University of Pennsylvania Perelman School of Medicine
                            Biography
                              The June Lab is primarily responsible for developing new CARs and new vectors for current and proposed indications. This lab also fosters the development of Penn students both in doctoral and post-doctoral programs. The June Laboratory provides researchers with the tools they need to translate laboratory insights into safe and effective cancer therapies. The June Laboratory works with University of Pennsylvania faculty members interested in moving biologically-focused research ideas into clinical trials. In addition, the June Laboratory has a cadre of faculty researchers focused on developing ways to enhance the ability of the natural immune system to recognize and eliminate tumor cells. Translational research is a core unit of the The Leonard and Madlyn Abramson Family Cancer Research Institute at the Abramson Cancer Center at the University of Pennsylvania. Created in December 1997 with a $100 million pledge from the Abramson Family Foundation, the Cancer Research Institute integrates research, education, and comprehensive patient care at the Abramson Cancer Center at the University of Pennsylvania. For more information, see the Translational Research Mission Statement.
                            • Janet Patterson Kane, PhD
                              Expert Veterinary and Biomedical Scientist, Morris Animal Foundation
                              Biography

                                Dr. Patterson-Kane received her veterinary degree and PhD from Massey University, New Zealand. She completed specialty training in the field of veterinary anatomic pathology at the University of Florida followed by the University of Kentucky, before becoming board-certified in 1999. Dr. Patterson-Kane was a faculty member at the Royal Veterinary College (University of London), and then the University of Queensland (Australia), before holding the Chair in Veterinary Pathology at the University of Glasgow (United Kingdom). After leaving academia in 2014 she worked in private diagnostics and the biotechnology industry before joining the Morris Animal foundation as Chief Scientific Officer in 2019.

                                Dr. Patterson-Kane’s research interests are broad, including cellular stress and ageing, and cancer pathology. She is co-author of the only currently available equine oncology textbook, ‘Clinical Equine Oncology’.

                              • Warren Kibbe, PhD
                                Vice Chair and Professor of Biostatistics and Bioinformatics at Duke University
                                Biography
                                  Warren A. Kibbe, PhD is Vice Chair and Professor of Biostatistics and Bioinformatics at Duke University, and the chief of the Division of Translational Biomedical Informatics. His research interests include data representation for clinical trials, especially improving the computability and interpretability of biomarker and eligibility criteria; data interoperability between medical records and decision support algorithms; improving data representation and interoperability for biomedical research using ontologies, developing novel analysis and visualization tools for next gen sequencing data, especially methylseq. Prior to joining Duke, he served as an acting deputy director of the NCI and was the director of the NCI's Center for Biomedical Informatics and Information for four years. He was one of the architects of the Genomic Data Commons initiative, which was the NCI's foray into creating a highly accessible and highly accessed cancer data repository for clinical, proteomic, imaging and genomic data. Dr. Kibbe has been a proponent for open science and open data in biomedical research and helped define the data sharing policy for the NCI Cancer Moonshot program. He also helped architect the joint NCI-DOE computational and biomedical research collaboration. Dr. Kibbe is the co-Founder of the Cancer Informatics for Cancer Centers (Ci4CC.org) society, and through Ci4CC organized twice-yearly meetings of cancer informatics faculty and leaders from the majority of NCI-designated Cancer Centers.
                                • Mark Kieran, MD, PhD
                                  Senior Director of Pediatric Oncology, Bristol-Myers Squibb
                                  Biography
                                    Dr. Kieran is currently the Senior Director of Pediatric Oncology, Bristol-Myers Squibb. He received a PhD in Immunology in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. After a post-doctoral fellowship in the Department of Molecular Biology at the Pasteur Institute in Paris, France where he cloned the regulatory molecule NFkB, he completed a pediatric residency at McGill University in Montreal and a pediatric oncology fellowship at Boston Children's Hospital. Dr. Kieran was named Director of Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute in 1998 until his move to BMS in 2018. While in Boston, he developed a large number of first in pediatric clinical trials in the areas of targeted therapeutics, gene therapy, anti-angiogenic modalities and immunotherapy. His ongoing interests include the genomic identification of mutations and incorporation of targeted, biologic, immune and gene therapy for children with cancer. He is currently also on the Medical Staff at Children's Hospital of Philadelphia.
                                  • Amy LeBlanc, DVM DACVIM
                                    Director, Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
                                    Biography
                                      Amy LeBlanc is board-certified veterinary oncologist and the Director of the intramural National Cancer Institute's Comparative Oncology Program. In this position she conducts preclinical mouse and translational canine studies that are designed to inform the drug and imaging agent development path for human cancer patients. She also advises leading pharmaceutical companies as well as NCI's Division of Cancer Treatment and Diagnosis on the inclusion of pet dogs with cancer into the development path of novel approaches for a variety of malignancies, including immunotherapeutics, targeted small molecules, oncolytic viruses, and cancer imaging agents. She directly oversees the NCI Comparative Oncology Trials Consortium (COTC), which provides infrastructure necessary to connect participating veterinary academic institutions with stakeholders in drug development to execute fit-for-purpose comparative clinical trials in novel therapeutics and imaging agents. Dr. LeBlanc obtained her veterinary degree from Michigan State University, and completed post-graduate training in small animal medicine, surgery and oncology at Texas A&M University and Louisiana State University. Prior to her appointment at NIH, Dr. LeBlanc was an Associate Professor with tenure and Director of Translational Research at the University of Tennessee College of Veterinary Medicine (CVM) and UT Graduate School of Medicine (GSM). Dr. LeBlanc's group at the University of Tennessee published the first comprehensive studies describing molecular imaging of dogs and cats using PET/CT, focusing on the forward and back-translation of 18F-labelled radiopharmaceuticals.
                                    • Dean Lee, MD, PhD
                                      Professor of Pediatrics and DiMarco Family Endowed Chair in Cell Based Therapy at Nationwide Children's Hospital
                                      Biography

                                        Brief Faculty Profile - Dr. Lee is Professor of Pediatrics and DiMarco Family Endowed Chair in Cell Based Therapy at Nationwide Children's Hospital. He is the founding Director of the Cellular Therapy and Cancer Immunotherapy Program, a joint program between NCH and The Ohio State University James Cancer Hospital. Dr. Lee conducts clinical and translational research on natural killer (NK) cells and their potential for cancer immunotherapy. His laboratory identified a crucial role for IL-21 and STAT3 signaling in NK cell function and proliferation, which has enabled a method for large-scale propagation of clinical-grade NK cells for adoptive transfer. NK cells expanded with this approach have been infused into adult and pediatric patients with leukemia, brain tumors, and solid tumors in investigator-initiated Phase I trials. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Novel and Exceptional Technology and Research Advisory Committee and member of the Cell Therapy Steering Committee of the Children's Oncology Group. His work in cancer immunotherapy and cellular therapy has been supported by NIH, DOD and numerous foundation research grants, and has led to over 100 peer-reviewed publications, patents, and commercial licenses. Dr. Lee practices clinically in the area of bone marrow transplantation, with a particular interest in haplotransplantation and cellular therapy.

                                      • Cheryl London, DVM, PhD, ACVIM
                                        Research Professor at Cummings School of Veterinary Medicine, Tufts University & Molecular Oncology Research Institute at Tufts Medical Center
                                        Biography
                                          Cheryl London, DVM, PhD, ACVIM (Oncology) is a Research Professor at Cummings School of Veterinary Medicine at Tufts University and the Molecular Oncology Research Institute at Tufts Medical Center. She has an active laboratory research program centered on comparative and translational oncology and is involved in the training of graduate students and postdoctoral fellows. She has recently joined the Clinical Trials Office at Cummings School to expand operations and enhance capacity and breadth of trials performed in client owned animals. Dr. London is also an Associate Faculty Professor at the Ohio State University College of Veterinary Medicine (OSU CVM) where she remains Director of the Clinical Trials Office at the CVM and Director of Translational Therapeutics at the Center for Clinical and Translational Sciences, OSU College of Medicine. Prior to her time at OSU, she was an Assistant Professor in the Department of Surgical and Radiological Sciences at the University of California, Davis. Dr. London earned her DVM at Cummings School, completed her Residency in Medical Oncology at the University of Wisconsin-Madison and received her PhD in Immunology at Harvard University, where she was also a postdoctoral fellow in the Department of Pathology.
                                        • Nicola Mason, BVetMed, PhD
                                          Professor of Medicine & Pathobiology, University of Pennsylvania School of Veterinary Medicine
                                          Biography

                                            Our translational research program focuses on a comparative approach, utilizing immunologically intact, canine patients with spontaneous cancer. This comparative approach provides a unique opportunity to evaluate the safety and effectiveness of next generation immunotherapies in a parallel canine patient population that presents the same challenges to effective immunotherapy as seen in human patients. The aim of this approach is to accelerate the translation of the most promising pre-clinical discoveries into the human clinic. Our lab is actively involved in developing the canine "model" for evaluating CART cell therapies. We have successfully translated several promising strategies to generate anti-tumor immunity from the lab and pre-clinical murine models into client owned dogs suffering from lymphoma, osteosarcoma and hemangiosarcoma. Our lab evaluates the immunological consequences of immune-based therapies in client owned dogs using flow cytometric phenotyping and functional assays including cytokine production, cytotoxicity assays and ELISpot assays to investigate canine T cell responses. Dr. Mason leads a multi-institutional clinical trial evaluating the safety and efficacy of a recombinant Listeria to prevent metastatic disease in dogs with osteosarcoma. She also leads the coordinating center for Canine Cancer Immunotherapy Trials (U24) as part of the Cancer Moonshot program. The lab has extensive experience in methodology to robustly expand and genetically modify canine T cells ex vivo and is the first to perform clinical trials using CART cells in client owned dogs with treatment naïve or relapsed B-NHL. This single site trial is performed at the Veterinary Hospital of the University of Pennsylvania.

                                          • John Otridge, PhD
                                            Director of Program Management for the Center for Technical and Operations Support
                                            Biography

                                              John Otridge has a PhD in Molecular Biology and completed a postdoctoral fellowship at NHGRI but left the laboratory behind in 2000 and joined Celera Genomics. Since then, John has worked in professional software development and service delivery for the life science community (clinical, diagnostics and research). In 2015 Dr. Otridge joined the Frederick National Laboratory for Cancer Research (operated by Leidos Biomedical Research) as a Technical Project Manager managing a diverse range of NCI sponsored projects and in July 2017 he became Director of Program Management for the Center for Technical and Operations Support (CTOS) group within the Biomedical Informatics and Data Science Directorate. His team have many projects underway for NCI and NIAID, with a large focus on developing and supporting NCI’s Cancer Research Data Commons which contains the Integrated Canine Data Commons.

                                            • Rodney Page, DVM, MS
                                              Professor and Director of the Flint Animal Cancer Center Stephen Withrow Presidential Chair in Oncology
                                              Biography

                                                Dr. Rodney Page, Director of the Flint Animal Cancer Center Professor and Director of the Flint Animal Cancer Center Stephen Withrow Presidential Chair in Oncology College of Veterinary Medicine and Biomedical Sciences Colorado State University Dr. Page received his DVM from Colorado State University and completed specialty training in the field of medical oncology in NYC. Dr. Page is board-certified in Internal Medicine and Oncology. He was a faculty member at North Carolina State University prior to his appointment at Cornell University as the founding director of The Sprecher Institute for Comparative Cancer Research. In 2005 Dr. Page was appointed Chair of the Department of Clinical Sciences. Dr. Page returned to Colorado as the Director of the Flint Animal Cancer Center in 2010 (www.csuanimalcancercenter.org ). Dr. Page has authored or co-authored about 130 peer-reviewed manuscripts, 30 book chapters and co-edited the 5th Edition of Withrow & MacEwen's Small Animal Clinical Oncology in 2012. Dr. Page's research interests have recently been focused on a 'One Medicine' approach to cancer. He has served as PI of the Golden Retriever Lifetime Study since 2008 and has initiated a national effort to bring translational and comparative oncology to a greater audience.

                                              • Gregory Reaman, MD
                                                Associate Director for Pediatric Oncology in the FDA's Oncology Center of Excellence, Office of the Commissioner
                                                Biography

                                                  Gregory Reaman is the Associate Director for Pediatric Oncology in the FDA's Oncology Center of Excellence, Office of the Commissioner and Associate Director for Pediatric Oncology in the Office of Oncologic Diseases, CDER. He is the Executive Director emeritus of the Center for Cancer and Blood Disorders and senior attending physician at Children's National, Washington, D.C.. He has held numerous leadership positions in clinical trial groups and professional organizations. He was the Inaugural Chair of the Children's Oncology Group and previously served as the Associate Chair for New Agent Studies and Vice Chair for Scientific Affairs of the Children's Cancer Group. He served on the national Board of Directors of the American Cancer Society and chaired its Task Force on Cancer in Children and on the Board of Directors of the American Society of Clinical Oncology and is currently a member of the Board of Directors of the International Society of Pediatric Oncology. He was the first pediatrician member of the FDA's Oncologic Drugs Advisory Committee and the first chair of its Pediatric Subcommittee. He is a professor of pediatrics at the George Washington University School of Medicine and Health Sciences. His research interests are in the immunobiology and therapy of acute leukemia and the development of new cancer therapeutics for children. He has authored more than 330 peer-reviewed publications.

                                                • Adam Resnick, PhD
                                                  Director of Data Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
                                                  Biography
                                                    "Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children's Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is also responsible for all scientific and fiscal responsibility for projects within the Center including: center leadership, supervision of bioinformatics, genomics, visualization tools and software development for the data resource portal shared by various center initiatives. Adam's research is focused on defining the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors. His research lab studies cell signaling cascades and their alterations in pediatric brain tumors to elucidate the molecular and genetic underpinnings of each tumor in an effort to identify and develop targeted therapies. Adam serves as Scientific Chair for several consortia-based efforts, including the Children's Brain Tumor Tissue Consortium (CBTTC) and Pacific Pediatric Neuro-Oncology Consortium (PNOC), which include more than 20 pediatric hospitals across the globe. Adam earned a dual-bachelor's in neuroscience and English & literature from the University of Florida before completing a PhD in neuroscience from Johns Hopkins University in Baltimore, MD."
                                                  • Ryan Roberts, MD, PhD
                                                    Assistant Prof, Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital Principal Investigator, Center for Childhood Cancer, Nationwide Children's Hospital The Ohio State University
                                                  • Elias Sayour, MD, PhD
                                                    Assistant Professor of Neurosurgery, Pediatrics & Principal Investigator, RNA Engineering Laboratory in the Preston A. Wells, Jr. Center for Brain Tumor Therapy & UF Brain Tumor Immunotherapy
                                                    Biography

                                                      Elias Sayour, MD, PhD is an Associate Professor of Neurosurgery and Pediatrics and Principal Investigator of the RNA-Engineering Lab at the University of Florida. He is a NIH-funded investigator who functions as the Director of the Pediatric Cancer Immunotherapy Initiative (PCI2) of the UF Health Cancer Center and Vice Chair of the UFHCC Scientific Review Monitoring Committee. As a board-certified pediatrician and oncologist, Dr. Sayour has extensive translational experience as PI/Co-I on several human trials. His translational efforts are also focused on new pipeline technologies including a novel lipid-nanoparticle (NP) formulation that his team has pioneered for the immunologic treatment of cancer currently being tested in canine (pet dog) patients with terminal brain cancer before translation into dedicated human studies.​

                                                    • Joshua Schiffman, MD
                                                      CEO & Co-Founder, PEEL Therapeutics / Pediatric Hematologist-Oncologist
                                                      Biography

                                                        Dr. Schiffman is the CEO and Co-Founder of PEEL Therapeutics, delivering evolution-inspired medicine to patients (*PEEL = Hebrew word for elephant). Dr. Schiffman also co-founded ItRunsInMyFamily.com, an online family history collection tool. Dr. Schiffman is a Professor of Pediatrics and Investigator at Huntsman Cancer Institute at the University of Utah and the previous Medical Director for the Family Cancer Assessment Clinic. Dr. Schiffman graduated from the Brown University School of Medicine in 2000, followed by clinical training in Pediatrics and Pediatric Hematology-Oncology at Stanford University from 2000-2008. His academic research and now commercial efforts focus on evolutionary solutions to disease, like cancer resistance in elephants and anti-inflammatory molecules in newborns. Dr. Schiffman’s continues to be very interested in comparative oncology – specifically what dogs can teach us about cancer risk and how new therapeutics can help both dogs and human patients.

                                                      • Jay Storm, MD
                                                        Director, Translational Brain Tumor Laboratory, Children's Hospital of Philadelphia
                                                        Biography
                                                          Dr. Storm directs CHOP's translational brain tumor laboratory and maintains a research program focusing on cell signaling cascades in pediatric brain tumors. The goal of this research is to understand and identify potential targets that can be developed into clinical therapy. His team is also leading collaborative efforts to de-silo research by engaging in open source platforms and cloud-based sharing.
                                                        • Connie Sommers, PhD
                                                          Program Director at the ImmunoOncology Branch in the Developmental Therapeutics Program in the Division of Cancer Treatment & Diagnosis, National Cancer Institute
                                                          Biography

                                                            Dr. Connie Sommers is a Program Director at the ImmunoOncology Branch in the Developmental Therapeutics Program in the Division of Cancer Treatment and Diagnosis in the National Cancer Institute. Her grant portfolio covers all aspects of immuno-oncology including immune checkpoint therapies, adoptive cell therapies, combination therapies, and multiple preclinical model systems including canines. She has co-organized conferences on adverse events of immune checkpoint inhibitor therapy, cell-based therapies for the treatment of solid tumors, and combination radiation therapy and immunotherapy . Her research background is in breast cancer and T cell immunology.

                                                          • Jeff Trent, PhD, FACMG
                                                            President and Research Director of the Translational Genomics Research Institute (TGen)
                                                            Biography

                                                              Dr. Jeffrey M. Trent is President and Research Director of the Translational Genomics Research Institute (TGen) in Phoenix, Arizona.

                                                              Prior to forming TGen in 2002, Dr. Trent served for 10 years as the Scientific Director of the National Human Genome Research Institute at the National Institutes of Health in Bethesda, Maryland. Under his guidance, NHGRI's Division of Intramural Research became an internationally recognized research center in human genetics.

                                                              Dr. Trent's research has provided important insights into the genetic basis of cancer. He is the author of more than 400 manuscripts in the scientific literature, numerous book chapters, invited reviews, and has given hundreds of invited lectures. He has received numerous honors and awards, and has sat on the editorial boards of a dozen scientific publications. He specializes in developing and integrating novel "omic" technologies, supporting studies of molecular changes related to cancer risk and progression. He continues to participate in studies of other complex diseases in humans, and alongside Drs. Will Hendricks and Matt Huentelman is a leader of TGen's canine hereditary cancer program.

                                                              Dr. Trent's previous faculty positions included: The University of Arizona, where he was Deputy Director and Director for Basic Science of the Arizona Comprehensive Cancer Center; the University of Michigan, where he held the E. Maisel Endowed Professorship in Cancer Genetics, Professor of Human Genetics and Radiation Oncology, Head of the Cancer Biology Division of the Department of Radiation Oncology, and Deputy Director and Director of Basic Research for the Michigan Comprehensive Cancer Center. He also is a Diplomat of the American College of Medical Genetics.

                                                              Work in Dr. Trent's laboratory focuses on the study of genetic changes related to cancer predisposition and progression. He has worked the majority of his career on melanoma, recently serving as the Co-Principal Investigator with Dr. Patricia LoRusso, Yale University of the Stand Up to Cancer/Melanoma Research Alliance Melanoma Dream Team. The focus on that project was using molecularly-guided therapy for patients with BRAF wild-type (BRAFwt) metastatic melanoma. In addition to continuing work on germline genetic alterations associated with melanoma risk, his laboratory, in concert with Dr. Hendricks’, has been among the most active in identifying and understanding the somatic changes associated with canine melanoma. The canine is a critically important model of human disease, and in the case of melanoma the clear clinical association to the human is for the largely understudied mucosal melanomas.

                                                              Other work in his laboratory has been focused upon relating the recent advances in both molecular biology and cancer genetics of ovarian cancer. Specifically, he was one of the leaders of an international consortium which recently identified that Small Cell Carcinoma of the Ovary, hypercalcemic type, (SCCOHT) displays frequent inactivating germline and somatic mutations in SMARCA4. SCCOHT is an extremely rare, aggressive cancer affecting children and young women (average age of diagnosis 23yo compared to 63yo for the common epithelial ovarian cancers). Working with investigators at TGen (Will Hendricks), Mayo Clinic (Alex Sekulic), University of British Columbia (David Huntsman) and University of North Carolina (Buddy Weissman) they identified germline and somatic inactivating mutations in this SWI/SNF chromatin-remodeling gene in nearly all SCCOHT. The genetic changes lead to SMARCA4 protein loss in >95% of SCCOHT tumors but in only 0.4% (2/485) of other primary ovarian tumors. Work is underway to understand how this pathognomonic implicate SMARCA4 in SCCOHT oncogenesis.

                                                            • Roel Verhaak, PhD
                                                              Professor and Associate Director of Computational Biology, JAX Laboratory
                                                              Biography
                                                                We are a computational cancer biology lab with a research focus on the analysis of cancer genomics data to improve our understanding of cancer biology. We have a specialized research interest in understanding disease progression of brain tumors, particularly glioblastoma and glioma. We mostly use high throughput sequencing and computational analysis in our research.
                                                              • Andrea Webber, PhD
                                                                Assistant Head, Clinical Biomarkers Translational Oncology, Merck
                                                                Biography

                                                                  Andrea Webber received her PhD in molecular biology from Princeton University and went on to a postdoctoral fellowship at the University of Pennsylvania School of Medicine before joining Merck & Co., Inc. Over the course of her pharmaceutical career, she has worked in biomarker discovery and development in support of both Discovery and Clinical Research. Currently, she is Assistant Head of Clinical Biomarkers in Merck’s Translational Oncology department, providing a key link between the Translational Sciences and Merck’s Clinical Development teams. The Translational Oncology Biomarkers Team supports early- and late-stage development and leverages multiple assays and platforms to inform on Keytruda monotherapy and combination therapies. Specifically, Dr Webber leads the biomarker strategy for multiple product development teams including Melanoma, Head and Neck, and Liver cancers.

                                                                Posters

                                                                 LAST CALL FOR ABSTRACTS!

                                                                Submissions Due:

                                                                THIS IS YOUR LAST CALL TO SUBMIT ANY ABSTRACTS!

                                                                CLICK HERE TO SUBMIT YOUR POSTER

                                                                Overview

                                                                The Paws for a Cure Research Symposium (PFAC) welcomes submissions from all participants to present their research in a poster format.  The purpose of the Poster Session is to visually stimulate interest in pediatric-relevant canine comparative oncology research; to convey methods, results, and significance of their work; and to promote conversations and networking among Symposium participants.  Abstract submissions will be displayed in a poster session/Reception on September 29, 2020.  

                                                                To give promising young investigators an opportunity to discuss their comparative oncology research with colleagues from other fields and disciplines, four (4) Assistant Professor, Post-Doctoral trainee and Graduate Student finalists will be selected from the abstracts to give oral presentations during the 2020 Paws for a Cure Symposium.  

                                                                CRITERIA:

                                                                ​We encourage submission of abstracts spanning a range of comparative topics, with particular interest in pediatric-relevant research, including, but not limited to:

                                                                • Immunology
                                                                • Genomics
                                                                • Immunotherapy, to include combination therapies
                                                                • Other therapies of cancer
                                                                • Imaging
                                                                • novel drug delivery approaches

                                                                Submissions will be reviewed by a cross-disciplinary Scientific Review Committee. Abstracts selected for poster presentation will be notified ***.

                                                                The Committee will select four exemplary projects from the submitted abstracts who will be invited to give a 5-10 minute pre-recorded oral presentation to be featured in the Poster Hall of the virtual 2020 Paws for a Cure Symposium. These four presenters will also have an opportunity to interact with participants in a live chat/Q&A format.

                                                                 RULES FOR SUBMISSION:

                                                                • Submissions for poster session accepted from all participants (academic, industry, etc.) Eligible submissions for Young Investigator finalist (oral) presentations must come from junior faculty level or below (e.g. Assistant professor, Post-Doc or Graduate student)
                                                                • Participants must be registered for the 2020 Paws for a Cure Symposium.
                                                                • Only one Abstract submission per participant is allowed.
                                                                • Previously published manuscripts are not eligible.

                                                                ​KEY DATES:

                                                                 July 2nd, 2020 - 11:59 PT

                                                                Abstract Submission & Meeting Registration Site Opens

                                                                August 31st, 2020 - 11:59 PT

                                                                Abstract Submission Deadline

                                                                September 15, 2020

                                                                Notification of Acceptance of Abstracts for Poster Presentations

                                                                September 15, 2020

                                                                Notification of Abstract Finalists for Young Investigator plenary (oral) video presentation

                                                                ***If your abstract is NOT accepted for PFAC Symposium, you will be notified.

                                                                Abstracts will be made available to all registered participants and may be posted on the symposium or CNK Foundation website.  Your consent will be required during submission. 

                                                                Abstract Evaluation and Notification

                                                                 

                                                                • Abstracts will be peer-reviewed for clinical and/or scientific content, relevance to heartworm, and clarity of writing. 
                                                                • All research to be presented should have been conducted with due regard to ethical practices.  For human studies and animal studies, please provide indication of any reviews, or standards of care that were followed.  For example, review by an IRB, IACUC, VCSC, or following Good Clinical Practices. 
                                                                • Authors will be notified regarding abstract eligibility and acceptance by September 15, 2020.

                                                                 

                                                                Poster Session Specifics

                                                                Scientific posters will be displayed in the virtual Poster Hall of the of the 2020 Paws for a Cure Symposium virtual meeting on September 29 from 12:00 PM - 6:00 PM, EDT

                                                                  

                                                                For additional informationcontact the Poster Session Committee Chair, Ryan Roberts at Ryan.Roberts@nationwidechildrens.org.

                                                                 

                                                                 

                                                                 

                                                                Title Sponsors

                                                                Title Sponsors
                                                                 
                                                                 

                                                                in collaboration with 

                                                                 

                                                                 

                                                                Sponsors

                                                                 

                                                                 

                                                                 

                                                                 

                                                                 

                                                                 

                                                                 

                                                                If your company and organization would like to financially support the 2020 Paws for a Cure Research Symposium, please contact: Info@pawsforacuresymposium.com

                                                                 

                                                                Make A Donation

                                                                #GivingOnceSavesTwice

                                                                WITH ONE GIFT, YOU CAN SAVE TWO LIVES!

                                                                The Canines-N-Kids Foundation is committed to funding cutting edge research to help children and our canine best friends beat the devastating cancers they BOTH develop.

                                                                With one gift you can help us fund research that can help save two lives:

                                                                • $50 will fund one hour of cancer research
                                                                • $400 will fund one day of cancer research
                                                                • $2,500 will fund a week of research
                                                                • $10,000 covers costs for a month of research

                                                                You can also to make a special Tribute Donation in honor of a special child or canine on our "Tribute Donation" page.

                                                                It feels great to know that #GivingOnceSavesTwice!   Thank you in advance for your generous support!

                                                                Help

                                                                General LabRoots Questions

                                                                email support@labroots.com  

                                                                Virtual Events and Webinars

                                                                Supported Configurations

                                                                • Operating System Internet Explorer Firefox Chrome Safari
                                                                  Vista IE8+ FF10+ Chrome15+
                                                                  Windows 7 IE8+ FF10+ Chrome15+
                                                                  Windows 8 IE10 FF10+ Chrome15+
                                                                  Mac OS X   FF10+ Chrome15+ Safari5.1+
                                                                • Cookie settings: session cookies enabled
                                                                • Browser configuration must have JavaScript enabled
                                                                • Adobe Flash player 10.2 or later

                                                                To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                                                Internet Connection

                                                                • A minimum of 100Kbps is recommended for audio-only events
                                                                • A minimum of 300Kbps is recommended for speaker on-video events

                                                                Computer Equipment

                                                                • Screen Resolution: Minimum 1024x768
                                                                • Video Card: 65,000 colors minimum
                                                                • Sound card and speakers (or headphones) for hearing webcast in full format
                                                                • Audio Card: 16-bit minimum
                                                                • RAM: 512MB of free RAM

                                                                Firewall Protocol

                                                                • HTTP on port 80 or HTTPS on port 443
                                                                • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                                                • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                                                Work-At-Home Attendees

                                                                • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                                                For A Seamless Experience

                                                                When using a mobile device, FREE Mobile Apps are available:

                                                                - For viewing Webinars:

                                                                - For viewing Virtual Events

                                                                Attendee Guide

                                                                • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                                                Virtual Event and Webinar Support:

                                                                Continuing Education (CME/CE) Support

                                                                Loading Comments...
                                                                Show Resources
                                                                Event Countdown
                                                                • 0 Days
                                                                • 0 Hours
                                                                • 0 Minutes
                                                                • 0 Seconds
                                                                Attendees
                                                                • See more